Shots:

• The real-world data involves assessing of Spiriva Respima Inhalation Spray 1.25mcg + combination inhaled corticosteroid and long-acting beta2-agonist (ICS+LABA) vs increased dose of ICS+LABA or continuing high dose of ICS+LABA in patients with asthma
• The study resulted in 73% lower exacerbation rates and 76% lower hospitalization rates in comparison to increased dose of ICS+LABA for 12 months
• Spiriva Respimat (tiotropium bromide) is a 1.25mcg long term once-daily maintenance treatment of asthma for 6 years and older

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter